Cartesian Therapeutics (RNAC) Current Leases (2019 - 2026)

Cartesian Therapeutics (RNAC) has reported Current Leases for 8 consecutive years, with $4.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases rose 13.01% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (up 13.01% YoY), while the FY2025 annual figure was $4.2 million, up 45.6% from the prior year.
• Current Leases improved to $4.2 million in Q1 2026 per RNAC's latest filing, from $4.2 million in the prior quarter.
• Across five years, Current Leases topped out at $4.2 million in Q1 2026 and bottomed at $1.1 million in Q1 2022.
• Historically, Current Leases has averaged $2.5 million across 5 years, with a median of $2.2 million in 2024.
• Annual changes were most pronounced in 2025 — Current Leases jumped 66.17% — and 2026, when it gained 13.01%.
• Cartesian Therapeutics' Current Leases stood at $1.6 million in 2022, then surged by 34.7% to $2.2 million in 2023, then jumped by 31.63% to $2.9 million in 2024, then surged by 45.6% to $4.2 million in 2025, then increased by 0.84% to $4.2 million in 2026.
• Business Quant data shows RNAC's Current Leases at $4.2 million in Q1 2026, $4.2 million in Q4 2025, and $3.9 million in Q3 2025.